Shots: Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
Shots: A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy,…
To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Continuing the series for the disease of the month, PharmaShots brings a condensed report on Osteoporosis, a bone and tissue disorder October 20th is observed as…
Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research To continue the series for the disease of the month, PharmaShots brings this month a summary of the disease Amyotrophic Lateral Sclerosis (ALS), a rare…
Shots:Rick and John spoke about the trial design and the results from the P-II OraGrowtH210 Trial and P-II OraGrowtH212 trial evaluating LUM-201 to treat pediatric growth hormone deficiencyThey also elaborated on the timeline of the further clinical development of LUM-201The interview gives an understanding of Lumos Pharma’s vision to develop new therapies…

